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Abstract
Purposes of these studies were first; to determine whether or not Calcium(II)3(3,5-
diisopropylsalicylate)6(H20)6 [Ca(II)3(3,5-DIPS)6], a lipophilic calcium complex, could decrease
activated-platelet aggregation, and second; to determine whether or not it is plausible that
Ca(II)3(3,5-DIPS)6 decreases activated-platelet aggregation by facilitating the synthesis of Nitric
Oxide (NO) by Nitric Oxide Synthase (NOS). The influence of Ca(II)3(3,5-DIPS)6 on the initial
rate of activated-platelet aggregation was determined by measuring.the decrease in rate of increase
in transmission at 550 nm for a suspension of Thrombin-CaCl activated platelets following the
addition of 0, 50, 100, 250, or 500 gM Ca(II)3(3,5-DIPS)6. To establish that the Ca(lI)3(3,5-
DIPS)6-mediated decrease in aggregation was due to activation ofNOS, the effect of L-NMMA, an
inhibitor of NOS, on the inhibition of platelet aggregation by Ca(II)3(3,5-DIPS)6 was determined
using a suspension of activated platelets contaimng 0 or 250 ILtM Ca(II)3(3,5-DIPS)6 without .or
with mM L-NMMA. An in vitro Bovine Brain NOS reaction mixture, containing CaC12 for the
activation of Phosphodiesterase-3’,5’-Cyclic Nucleotide Activator required for the activation of
NOS, was used to determine whether or not Ca(II)3(3,5-DIPS)6 could be used as a substitute for the
addition of Ca. The decrease in absorbance at 340 nm, lambda maximum for NADPH, was
measured to determine NOS activity following the addition of NOS to the complete reaction
mixture containing either CaCI_, Ca(II)3(3,5-DIPS)6, or neither Ca compound. Increasing the
concentration of Ca(II)3(3,5-DIPS)6 caused a concentration related decrease in activated platelet
aggregation. The addition of L-NMMA to activated platelets, in the absence of Ca(II)3(3,5-DIPS)6,
caused a 129% increase in initial rate of platelet aggregation. The initial rate of plate_let
aggregation decreased 74% with the addition of 250 gM Ca(II)3(3,5-DIPS)6 and the addition of
NMMA plus 250 tM Ca(II)3(3,5-DIPS)6 caused a 197% decrease in initial rate of aggregation
compared to the initial rate observed with the presence of mM L-NMMA alone. There was only
0 a small, 27, increase in initial rate of 0.4 mMNADPH oxidation when 0.9 mM CaCI2 was added
to the NOS reaction mixture in comparison to the initial rate ofNADPH oxidation with no addition
of CaCI2. Addition of an equivalent amount of Ca in the form of Ca(II)3(3,5-DIPS)6, 333 ILtM,
caused a 37% increase in initial rate of NADPH oxidation compared to the addition of 0.9 mM
CaCI2. Addition of increasing concentrations of L-NMMA plus 0.9 mM CaCI2 or 333
Ca(II)3(3,5-DIPS)6 to the NOS reaction mixture caused a concentration related increase in initial
rate o NADPH oxidation. Addition of -NMMA while expected to decrease NADPH oxidation
actually increased the rate of NADPH oxidation. Additions of 133 ILtM or 267 ILtM Ca(II)3(3,5-
DIPS)6 also caused concentration related increases in initial rate of NADPH oxidation in the
resence of 113 laM L-NMMA. However, the addition of 533 gM Ca(II)3(3,5-DIPS)6 caused a
ramatic decrease in initial rate ofNADPH oxidation by NOS. It is concluded that: 1) Ca(II)3(3,5-
DIPS)6 activates platelet NOS in preventing platelet aggregation, 2) in vitro NOS activity can be
observed spectrophotometrically by following the consumption of NADPH as a decrease in
absorbance at 340 nm, 3) Ca(II)3(3,5-DIPS)6plays a role in enhancing Bovine Brain NOS activity
resulting in an increased rate ofNADPH oxidation by NOS, 4) Ca(II)3(3,5-DIPS)6 is a useful form
of Ca in activating NOS and superior to CaCI2 with regard to the facilitauon of a NADPH
oxidation, and 5) .-NMMA stimulates Bovine Brain NOS activity rather than causing an inhibition
of this enzyme and must serve as a reducible substrate for Bovine Brain NOS.
Introduction
Nitric Oxide (NO), synthesized by Nitric Oxide Synthase (NOS) mediates physiological
responses including" neuronal transmission, consciousness, dilation of blood vessels, leukocyte
destruction of invading pathogens and cancer cells, leukocyte responses in inflammation, pain
perception, and decreased platelet adhesion and aggregation [1,2 and references therein].
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Nitric Oxide and L-Citrulline are formed via a reduced nicotinamide-adenine-dinucleotide-
3’-phosphate (NADPH)-dependent enzymatic oxidation of L-Arginine by NOS. There are two
forms of NOS. The constitutive form of NOS is reversibly activated by the Ca-dependent
Phosphodiesterase-3’,5’-Cyclic Nucleotide Activator known as Calmodulin, which is activated by
an influx of Ca into the cells or mobilization of stored Ca. The inducible form of this enzyme is
activated by white blood cell derived cytokines [1].
Cellular uptake of Ca is actively regulated in part by NO activation of Guanylyl Cyclase,
the subsequent synthesis of cyclic guanosine monophosphate, and the release of Glutamic acid
which in turn opens Ca channels allowing Ca to enter cells, e.nabling the activation of Calmodulin.
The form of Ca entering platelets is generally depicted as hydrophillic, non-lipophilic, ionically
bonded Ca [3].
Since a more lipophilic form of Ca may be able to undergo translocation across platelet
membranes in a passive process, Calcium(II)a(3,5-diisopropylsalicylate)6(HzO)6 [Ca(II)3(3,5-
DIPS)6], a lipophilic Ca complex, was examined for its effects on platelet aggregation. Platelet
aggregation was studied in an activated-platelet system containing mM ionically bonded Ca, in
the form of CaCI_, and Thrombin, both being required for llatelet aggregation [4].
The monomethyl derivative of L-Arginine, N’-monomethyL-L-Arginine (L-NMMA), is
suggested to inhibit NOS following bonding to the active oxidation domain of NOS and prevent
the production ofNO causing an increase in platelet aggregation [2,4]. This inhibitor ofNOS was
viewed as useful in determining whether or not Ca(II)3(3,5-DIPS)6 inhibits platelet aggregation by
activation of NOS and determining whether or not L-NMMA inhibits the Ca(II)3(3,5-DIPS)6-
mediated inhibition of platelet aggregation.
Materials and Methods
Tetrahydrobiopterin (THB), NADPH, L-NMMA, Calmodulin, , L-Dithiothreitol (DTT),
flavin adenine dinucleotide (FAD), L-Arginine, Bovine Brain NOS, Thrombin, CaCI_ (all from
Sigma Chemical Company), 4-(2-hydroxyethyl)-l-piperazinethane-sulfonic acid (HEPES)
(Aldrich Chemical Company) and 3,5-diisopropylsalicylic acid (Hochem Enterprise) were used as
purchased without further purification.
Calcium(II)3(3,5-DIPS)6 was synthesized as follows. One hundred grams (0.45 mol) of
3,5-diisopropylsalicylic acid was dissolved in two liters of deionized water wth 29.7 g (0.45 mol)
of KOH wth vigorous stirring. The resultingsolution was adjusted to pH 9.0 with 10%
h),drochloric acid and filtered wth a sintered glass funnel. A solution of CaCI was prepared by
dssolving 36.39 g (0.50 tool) CaCI_(H_O)2, a 10% excess of Ca, in 500 ml of ddionized water and
filtered tlarough a sntered glass funnel. The CaCIz solution, pH 7.3, was added dropwise with a
separatory funnel to a vigorously stirred solution of potassium 3,5 diisopropylsalicylate. Vigorous
stirring was employed to cause shearing of the precipitating Ca complex particles and avoid
entrapment of the reactant and potassium chloride in the precipitating reaction product. Following
completion of this addition, the product was collected by filtration with a sintered glass funnel and
air dried overnight in the filter funnel attached to laboratory vacuum, 15 mm Hg. A 78% yield,
84.7 g, of a wfiite solid melting over the range of 2400 to 243C was obtained using these
procedures. X-ray crystallography revealed that the complex is a linear trinuclear hexahydrate,
Ca(II)3(3,5-DIPS)6(H_O)6, hexakis-g-3,5-diisopropylsalicylatohexaaquotricalcium(II) [Professor
Wally Cordes, personal communication]. Elemental composition calculated for C78HII4024Ca3: C,
60.24% and H, 7.33%. Found values were: C, 60.23% and H, 7.04%.
Rat platelets were collected prior to their use on the day they were used and maintained in
a platelet buffer containing HEPES, Sodium Chloride, Potassium Chloride, Glucose, and
Indomethacin, added to inhibit cyclooxygenase activity. Ultraviolet and visible absorbances were
measured with a Hewlett Packard 8452A Diode Array Spectrophotometer. All glassware was
thoroughly cleaned with either aqua regia or Citronox (Alconox Inc.) and all plasticware was
metaL-free polypropylene. Deionized water, pH 7.5, was used throughout.
Platelet Inhibition Studies: A 100 mM Ca(II)3(3,5-DIPS)6 solution was prepared by
dissolving 1.55 g (1 mmol) in enough absolute ethanol to make the final volume 10 ml.
Approximately 12 ml of rat blood was centrifuged at 150 x g for 20 minutes. The separated
plasma was then centrifuged at 800 x g for 15 minutes to obtain a platelet pellet. A stock
suspension of platelets was prepared by adding 10 ml of buffer to the platelet pellet and gently
shaking the solution. A stirring magnet, ml of buffer, 500 lal of platelet suspension, 7.5 gl of
ethanol, and 37.5 gl of 250 laM CaCI_ were placed in a 4 ml cuvette. Using a Hitachi
spectrophotometer, the percent transmission was recorded at 550 nm for two minutes. One
hundred micro units of Thrombin (15 lal) was then added five seconds after the recording of
percent transmission began. These spectrophotometric recordings were repeated with the
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replacelnent of the 7.5 tl of etha.nol with 7.5 tl of 2, 10, 20, 50, or 100 mM ,ethanolic Ca(II)3(3,5-
DIPS)6 to give a final concentration of 10, 50, 100, 250, or 500 taM Ca(II)3(o,5-DIPS)6. Platelets
were also incubated with mM I-NMMA for 5 minutes or with 250 btM Ca(II)3(3,5-DIPS)6 and
mM -NMMA and percent transmission determined over a period of two minutes to determine
effects of these two compounds on the rate of activated platelet aggregation. Data are presented as
the average of 3 to 5 determinations following the addition of the examined COlnpounds.
The rate of aggregation of activated platelets was measured as the time-dependent increase
in transmission of incident irradiation. The initial rate of aggregation was determined by
measuring the increase in transmission per second. Percent inhibition of the rate was calculated by
subtracting the observed initial rate of aggregation for the activated platelet reaction mixture
containing no Ca(II)3(3,5-DIPS)6 from the observed initial rate of aggregation of activated platelets
for the reaction mixture containing Ca(II)3(3,5-DIPS)6, dividing by the initial rate of aggregation
for the activated platelet reaction mixture containing no Ca(II)3(3,5-DIPS)6, and multiplying by
100.
In Vitro Studies ofNitric Oxide Synthase: An 80 mM HEPES buffer (pH 7.3) containing
1.5 mM CaCI_ (CaCI_ Buffer) was prepared by dissolving 19.064 g of HEPES and 0.2205 g of
CaCI_ in enough deionized water to make the final volume one liter. To prepare a 3.4 mM L-
Arginine solution, 7.164 nag (34 lumol) was dissolved in enough CaCI_ Buffer to make the final
volume 10 ml. An 80 mM HEPES buffer (pH 7.3) containing no Ca (Buffer) was prejgared by
dissolving 19.064 g (80 retool) of HEPES in enough deionized water to make the final votume one
liter. A mM Ca(II)(3,5-DIPS)6 solution was prepared by dissolving 1.55 g (10 retool) of
Ca(II)3(3,5-DIPS)6(H_Oi6 in enough Buffer to make the final volume 10 ml. To prepare a 20 mM
DTT solution, 18.02 mg (0.2 retool) was dissolved in enough Buffer to make the final volume 5
ml. To prepare a mM THB solution, 3.142 mg (10 btmol) was dissolved in enough Buffer to
make the final volume 10 ml. This solution was made immediately before use. To prepare a 1.0
mM FAD solution, 2.295 mg (10 lamol) was dissolved in enough Buffer to make the final volume
10 ml. To prepare a 3.0 mM NADPH solution, 2.5 mg (30 gmol) was dissolved in enough Buffer_
to make the final volulne 10 ml. To prepare a 5000 u,nit/ml Calmodulin solution, 10,000 units of
Calmodulin were dissolved in two lnlofBuffer. A .4 mM L-NMMA solution was prepared by
dissolving 3.38 nag (17 gmol) ofL-NMMA in enough Buffer to make the final volume 5 ml.
Using the_ Hewlett Packard 8452A Diode Arra}’ spectrophotometer with a cuvette magnetic
stirrer, spectra of DTT, THB, FAD, L-NMMA, L-Arglnine, Ca(II)3(3,5-DIPS)6, and NADPH were
recorded throughout the range of 200 nm to 800 nm. One tenth of a ml of a 5000 unit/ml
Calmodulin, 0.9 ml of Buffer, 0.1 ml of the DTT solution, 0.1 ml of the mM THB solution, and
0.025 ml of the mM FAD solution were added to the cuvette, stirred, and maintained at 37C.
Then, 50 gl of the 3.4 mM L-Arginine solution, 200 1 of the 3 mM NADPH solution, and 25 btl of
NOS were added to the cuvette. The change in absorbance at 340 nm was recorded every minute
for fifteen minutes after the addition ofNOS. This experiment was repeated using 0.9 ml of CaCI2
Buffer in place of the Buffer lacking CaCI2.
To measure the effect of Ca(II)3(3,5-DIPS)6 on NOS, 0.1 ml of 5000 unit/ml Callnodulin,
0.4 1hi of" Buffer, 0.5 ml of the mM Ca(II)3(3,5-DIPS)6 solution, 0.1 ml of the DTT solution, 0.1
ml of the 1riM THB solution, and 0.025 ml of the mM FAD solution were added to the cuvette
and stirred at 37C. Then, 50 gl of the 3.4 mM L-Arginine solution, 200 lul of the 3.0 mM NADPH
solution, and 25 .tal of NOS were added to the cuvette. The change in absorbance at 340 nm was
recorded every minute for fifteen minutes after the addition ofNOS.
To measure the effect of the NOS inhibitor -NMMA on the NOS enzym( system, 0.1 ml
of a 5000 unit/ml Calmodulin, 0.85 ml of CaCI2 Buffer, 0.1 ml of the DTT solution 0.1 ml of the
mM THB solution, and 0.025 ml of the mM FAD solution were added to the cuvette and stirred
at 37C Then, 50 lul of the 3.4 mM -Arginine solution, 50 lal of the 3.4 mM -NMMA solution,
200 btl )f the 3 mM NADPH solution, and 25 btl ofNOS were added to the cuvette. The change in
absorbance at 340 nln was recorded every minute for fifteen minutes after the addition of NOS.
This experiment was repeated by replacing 200 lul or 400 gl of CaCI2 Buffer with 200 btl or 400
of-NMMA solution.
To determine the effect of-NMMA on NOS in the presence of Ca(II)3(3,5-DIPS)6, 0.1 ml
of 5000 unit/ml Calmodulin, 0.5 ml of the mM Ca(II)3(3,5-DIPS)6 solution, 0.1 ml of the DTT
solution, 0.1 ml of the mM THB solution, and 0.025 ml of the mM FAD solution were added to
the cuvette and stirred at 37C. Then, 50 btl of the 3.4 mM -Arginine solution, 40 btl of the 3.4
mM .-NMMA solution, 200 btl of the 3.0 mM NADPH solution, and 25 btl of NOS were added to
the cuvette. The change in absorbance at 340 nm was recorded every lninute for fifteen minutes
after the addition of NOS. This experiment was repeated using 0.05 ml of 3.4 mM -NMMA and
0.2 ml, 0.4 ml, 0.5 ml, or 0.8 ml of lnM Ca(II)3(3,5-DIPS)6 solution and enough Buffer to make
the final volume 1.5 ml. For each experiment involving the addition of CaC12, Ca(II)3(3,5-DIPS)6,
and/or L-NMMA to the NOS reaction mixture the decrease in absorbance at 340 nm was plotted
over a 15 lninute period. To obtain the initial rate ofNADPH oxidation, the decrease in 340 nm
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absorbance observed over the first five minutes was used to obtain a regression plot at the 95%
confidence level using Sigma Plot (Jandel Corporation). Other statistics including r-, the goodness
of fit, and m, the slope, were also obtained at the 95% confidence level with the Sigma Plot
program These regression plots vyere used to calculate the initial rate of the enzyme catalyzed
reaction asing the formula: AA rain" x 100.
Results
Initial studies demonstrated that the use of ethanol to make additions of Ca(II)3(3,5-DIPS)6
to the reaction mixture had no effect on aggregation of platelets activated with the addition of
CaCI2 plus 100 gU of Thrombin. The initial rate for the increase in percent transmission of the 600
nm incident irradiation, associated with aggregation of platelets, following the addition of 75 lul of
ethanol was 0.7 percent transmission/second (%T/s) versus 0.6 %T/s for the aqueous system
containing no ethanol.
In addition, Ca(II)3(3,5-DIPS)6. did not serve as a more bioavailable source of Ca when
compared to CaCI2 in enabling Thrombin activation of platelets. The initial rate of aggregation of
activated platelets in the presence of gM CaCI2 was 0.1%T/s versus 0.15 %T/s when up to 500
gM Ca(II)3(3,5-DIPS)6 was added to the reaction mixture instead of CaCI2. This addition of
Ca(II).(3,5-DIPS)6 represented a 1500 fold increase in the amount of Ca supplied by the addition
of gM CaCl2 required to activate platelets.
Increasing the concentration of Ca(II)3(3,5-DIPS)6 added to the Thrombin and CaCI2
activated platelet system caused a concentrated related decrease in platelet aggregation, as shown
in Figure and Table I. Consistent with this, the percent inhibition of the initial rate of platelet
aggregation increases as the concentration of Ca(II)3(3,5-DIPS)6 increased as shown in Table 1.
Figure 1 Initial rate ofaggregation following the
additionfCa(II)(3,5-DIPS)6 to activated platelets.
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Table I. Initial rate of platelet aggregation and percent inhibition in the presence of increasing
concentrations of Ca(II) 3(3,5-DIPS)6.
Concentration of Initial Rate of Aggregation Percent
Ca(II) (3,5-DIPS)6 (gM) (% increase in transmission/sec) Inhibition
0 0.87 0
50 0.44 50
100 0.29 67
250 0.22 75
500 0.15 83
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As shown in Figure 2 and Table II, additions of Ca(II)3(3,5-DIPS)6 caused a decrease in
platelet aggregation in the presence or absence of L-NMMA. The initial rate of aggregation for
CaCI_ and Thrombin activated platelets was 0.31%Y/s. Addition of 250M Ca(II)3(3,5-DIPS)6 to
the reaction mixture decreased the initial rate of aggregation of these platelets to 0.08 %T/s, nearly
a four-fold decrease in rate of aggregation. Incubation of activated platelets with mM L-NMMA
increased the rate of aggregation to 0.71%T/s, a two-fold increase in rate of aggregation. Addition
of both 250 gM Ca(II)3(3,5-DIPS)6 and mM L-NMMA caused a reduction of the initial rate of
aggregation to 0.10 %T/s, a seven-fold decrease in aggregation compared to the aggregation
observed for the addition of L-NMMA alone. The percent decrease in rate of aggregation, shown
in Table 2, reveals that Ca(II)3(3,5-DIPS)6 alone prevents aggregation and enhanced aggregation
due to the addition of L-NMMA was also prevented by the addition of Ca(II)3(3,5-DIPS)6 (Table
2).
Figure 2. Effect Ca(II)3(3,5-DIPS)6(--) or
Ca(II)3(3,5-DIPS) plus L-NMMA (-) addition
on, o,,the initial rate of platelet aggregation.
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Table II. Effect of the addition of Ca(II)3(3,5-DIPS)6 or Ca(II)3(3,5-DIPS)6 plus L-NMMA on the
initial rate of platelet aggregation.
Concentration of Initial Rate of Aggregation Percent
Ca(II) 3(3,5-DIPS)6 (ruM) (% increase in transmission/sec) Inhibition
0 0.31 0
250 0.08 74
0 + -NMMA 0.71 129
250 + -NMMA 0.10 68
Nitric Oxide Synthase activity was determined by measuring the decrease in 340 nm
absorbance for the oxidation of NADPH by NOS in the conversion of -Arginine to -Citrulline
and NO. The addition of NOS to the incomplete reaction mixture containing no added Ca caused
the oxidation of NADPH as shown in Figure 3. The initial rate for this oxidation, 0.22 nm/min,
was calculated, AA rain x 100, using the regression plot (Figure 3a) for data obtained during the
first five minutes of NADPH oxidation. As shown in Figure 3a, data obtained over this period
were linear and had a good fit to this regression plot (r 0.98).
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Figure 3. Oxidation of0.4 mM NADPH
by Nitric Oxide Synthase in the absence
of 0.9 mM CaCI.
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Figure 3a. Initial rate for the oxidation
of0.4 mMNADPH by Nitric Oxide
Synthase in the absence of0.9mM CaCl2.
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The addition ofNOS to the complete reaction mixture containing 0.9 mM CaClz caused
the oxidation of NADPH shown in Figure 4, with an initial rate of 0.48 nm/min calculated using
data presented in Figure 4a. Table III is a summary of the initial rates of oxidation ofNADPH by
NOS, the decrease in absorbance at 340 nm during the first five minutes for each of these
experiments. There was a 27% increase in initial rate with the addition of CaCIz compared to the
incomplete reaction mixture containing no added CaCI.
Table III. Initial rate of400 gM NADPH oxidation by Nitric Oxide Synthase.
Addition or Deletion to the
Reaction Mixture
No added CaClz
0.9 mM CaCI_
333 laM Ca(II)3(3,5-DIPS)6
0.9 mM CaCI_ and 113/ttM
L-NMMA
0.9 mM CaCI_ and 453
L-NMMA
0.9 mM CaCl_and 907 gM
L-NMMA
333 gM Ca(II)3(3,5-DIPS)6 and
907 laM -NMMA
133 gM Ca(II)3(3,5-DIPS)6 and
113 gM -NMMA
267 [,tM Ca(II)3(3,5-DIPS)6 and
113 laM -NMMA
533 gM Ca(II)3(3,5-DIPS)6and
113 gM L-NMMA
*Average of 3 to 5 determinations
Initial Rate ofNADPH Oxidation
(decrease in A/min x 100)
0.26*
0.33*
0.45
Percent Change in Initial Rate
versus System with no CaClz
27
73
0.45 73
0.73 181
0.80 208
1.13 335
0.88 239
1.10 323
0.19 -27
Addition of 333 gM Ca(II)3(3,5-DIPS)6 increased the initial rate of NADPH oxidation
(Figures 5 and 5a) to 73% (Table III) compared to the incomplete reaction mixture containing no
added CaCI_
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Figure 4. Oxidation of0.4mMNADPH
by Nitric Oxide Synthase in the presence
of0.9mM CaCI.
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Figure 5. Oxidation of 0.4mMNADPH
by Nitric Oxide Synthase in the presence
of333 IxM Ca(II)3(3,5-DIPS)6.
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Figure 6. Oxidation of 0.4mMNADPH
by Nitric Oxide Synthase in the presence
of 0.9mM CaCI2 and 113 pM L-NMMA.
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Figure 4a. Initial rate for the oxidation
of0.4mMNADPH by Nitric Oxide Synthase
in the presence of0,9mM CaCI.
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Figure 5a. Initial rate for the oxidation
of 0.4mMNADPH by Nitric Oxide Synthase
in the presence of333 IM Ca(II)3(3,5-DIPS)6.
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Figure 6a. Initial rate for the oxidation
of0.4mM NADpH by Nitric Oxide Synthase
in the presence of 0.9mM CaC1/2 and
113 pM L-NMMA.
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Adding 113 laM k-NMMA to the complete reaction mixture containing CaC12 also
increased the initial rate ofNADPH oxidation (Figures 6 and 6a) to 73 % (Table Ill) in comparison
with the initial rate observed for the incomplete reaction mixture.
As shown in Table III the addition of 453 gM k-NMMA to the complete reaction mixture
containing CaCI_ caused a further linear increase in initial rate ofNADPH oxidation (Figures 7 and
7a)to 181%.
Figure 7. Oxidation of 0.4 mMNADPH Figure 7a. Initial rate for the oxidation
by Nitric Oxide Synthase in the presence of 0.4 mM NADPH by Nitric Oxide
of 0.9 mM CaCI and 453 i.tM L-NMMA. Synthase In the Presence of 0.9M
CaCI2 and 453 l.tM L-NMMA.
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With the addition of 907 laM -NMMA, there was a further linear (Figures 8 and 8a)
increase in initial rate of oxidation ofNADPH to 208% (Table Ill).
Figure 8. Oxidation of0.4mMNADPH
by Nitric Oxide Synthase in the presence
of0.9mM CaCI and 907 gM L-NMMA.
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Figure 8a. Initial rate for the oxidation
of0.4mMNADPH by Nitric Oxide Synthase
in the presence of0.9mM CaCI and
907 gM L-NMMA.
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Replacing the 0.9 mM CaCI with 333 gM Ca(II)3(3,5-DIPS)6 and adding 907 laM -
NMMA caused a still greater increase in initial rate of NADPH oxidation (Figures 9 and 9a) to
335% (Table Ill) compared to the reaction mixture without 0.9 mM CaCI2 and 127 % greater than
the reaction mixture containing 0.9 mM CaCI2 and 907 laM .-NMMA. However the time-
dependent decrease in absorbance was not as linear over the 15 min. period of measurement.
Increasing the concentration of Ca(II)3(3,5-DIPS)6 frorn 133 laM to 267 IaM and holding the
concentration of -NMMA at 113 gM caused further concentration related increases in initial rate
ofNADPH oxidation (Figures 10, 10a, 11, and la) from 239% to 323%, respectively, as shown in
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Table III. However, the linear decrease in measured absorbance only held through the first 5 rain.
of measurement.
Figure 9. Oxidation of 0.4 mM NADPH
by Nitric Oxide Synthase in the presenee
of 333 laM Ca(II)(3,5-DIPS) and
907 tM L-NMMA.
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Figure 9a. Initial rate for the oxidation
of 0.4 mM NADPH by Nitric Oxide Synthase
in the presence of 333 ttM Ca(II)3(3,5-DIPS)6
and 907 IM L-NMMA.
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Figure 10. Oxidation of 0.4 mM NADPH
by Nitric Oxide Synthase in the presence
of 133 I.tM Ca(II)a(3,5-DIPS) and
I 13 l.tM L-NMMA.
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Figure 10a. Initial rate for the oxidation
of 0.4 mM NADPH by Nitric Oxide Synthase
in the presence of 133 tM Ca(II)(3,5-DIPS)
and 113 tM L-NMMA.
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With a further increase in addition of Ca(II)3(3,5-DIPS)6 to 533 IaM, there was a dramatic
change in initial rate of NADPH oxidation (Figures 12 and 12a) to 27 % (Table III) of the
oxidation ofNADPH compared to the oxidation ofNADPH in the absence of added CaCI_, or only
22 % of the initial rate ofNADPH oxidation in the presence of 133 l.tM Ca(II)3(3,5-DIBS)6. This
decrease in initial rate ofNADPH oxidation appears to be due to an oxidation-reduction cyclingof
NADPH until the NADPH was eventually consumed.
This oxidation-reduction equilibrium rationale is consistent with the observed poor fit of
data to the fitted plot, r 0.01. This rationale is also consistent with the lack of smooth plots for
the decrease in absorbance versus time observed for these reaction mixtures, which is most
pronounced for the addition of 533M Ca(II)3(3,5-DIPS)6 (Figures 12).
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Figure 11. Oxidation of 0.4 mM NADPH
by Nitric Oxide Synthase in the presence
of267 ktM Ca(II)3(3,5-DIPS)6 and
113 IsM L-NMMA.
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Figure la. Initial rote for the oxidation
of 0.4 mMNADPH by Nitric Oxide Synthase
in the presence of267M Ca(II)3(3,5-DIPS)6
and 113 btM L-NMMA.
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igure 12. Oxidation of 0.4 mMNADPH
y Nitric Oxide Synthase in the presence
of 533 p.M Ca(II)(3,5-DIPS) and
113M L-NMMA.
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Figure 12a. Initial rate for the oxidatio
of0.4mMNADPH by Nitric Oxide Synthase
in the presence of533 tM Ca(II)a(3,5-DIPS)
and 113 IxM L-NMMA.
2.08
2.06
2.04
2.02-
2.00
1.98
Time (min)
Discussion
Calcium(II)3(3,5-DIPS)6, a lipophilic Ca complex, failed to serve as a source of Ca for
platelet activation in the presence of Thrombin since a 1500-fold increase in Ca concentration in
this form compared to CaCI_ failed to facilitate Thrombin-mediated aggregation. Calcium
Chloride, a hydrophilic form of Ca, is required for platelet activation and aggregation in the
presence of Thrombin.
Results presented in Figure show that as increasing concentrations of Ca(II)3(3,5-DIPS)6
are added to the activated platelet system, the initial rate of aggregation is decreased or the addition
of Ca(II)3(3,5-DIPS)6 to the activated platelet system caused a decrease in initial rate of
aggregation, an increase in percent inhibition of aggregation.
Interestingly, the addition of L-NMMA caused an increase in activated platelet aggregation
consistent with the suppression of endogenous platelet NOS synthesis of NO. Adding both L-
NMMA and Ca(II)3(3,5-DIPS)6 to the activated platelet system dramatically decreased the rate of
activated platelet aggregation, overcoming the increase in aggregation due to the addition of L-
NMMA alone, which is most likely due to the activation of NOS by Ca(II)3(3,5-DIPS)6 and
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synthesis of NO. This may be interpreted as activation of Calmodulin, which in turn activates
NOS.
This inhibition may be due to the passive translocation of Ca(II)3(3,5-DIPS)6 across
platelet plasma membrane and bonding of Ca via ligand exchange to activate Calmodulin
phosphodiesterase activity which in turn activates NOS leading to the synthesis of NO and
inhibition of platelet aggregation.
To examine the mechanism of Ca(II)3(3,5-DIPS)6 activation of NOS, there was a need to
determine whether or not this Ca complex serves as a bioavailable form of Ca in activating NOS.
Results presented in Figure 2 show that the addition of NOS to the incomplete reaction mixture
containing no added Ca caused a time related decrease in absorbance at 340 nm due to the
oxidation ofNADPH. Because NOS cannot be activated without Ca and therefore cannot oxidize
NADPH in the absence of Ca, the purchased Calmodulin must already be nearly fully Ca activated.
As shown in Table 2, the addition of CaCI2 caused only a small increase in rate of NADPH
oxidation by NOS. The addition of 333 laM Ca(II)3(3,5-DIPS)6 to the incomplete reaction mixture,
which represents the addition of the same molar concentration of Ca as in 0.9 mM CaClz caused an
additional increase in initial rate of NADPH oxidation by NOS in comparison with the complete
reaction mixture containin 0.9 mM CaCI_.
According to previous reports [2 and references therein], .-NMMA inhibits the activity of
NOS. Results presented in Figures 5 to 10 and Table 2 are inconsistent with these reports. As
increasing concentrations of -NMMA were added to the reaction mixture containing 0.9 mM
CaCI_, the rate of NADPH oxidation increased (Figures 5, 5a, 6, 6a, 7, and 7a). These results
suggest that -NMMA may not always inhibit NOS activity and that -NMMA actually serves as a
oxidizable substrate for NOS which leads to an increase in the consumption of NADPH. This is
consistent with the report by Hecker et al. [5] that -NMMA led to an increase in oxidation of -
Arginine and -Citrulline synthesis in cultured bovine endothelial cells in explaining why -
NMMA was less effective than -Na-nitroarginine methyl ester (-NAME) in inhibiting rabbit
aortic ring relaxation and in increasing blood pressure in anesthetized rats. It was suggested that a
novel deaminase, a N,-Na-dimethylarginine dimethylaminohydrolase, might be used to account
for the conversion of -NMMA to -Citrulline, which was then metabolically converted to -
Arginine. In addition to this plausible accounting for increased NO synthesis with the addition of
.-NMMA, it is also plausible that the P-450-mimetic activity suggested for NOS [6] might convert
-NMMA to -Arginine and formaldehyde. This P-450-mimetic activity and the increased
concentration of -Arginine would account for the increased rate ofNADPH consumption in the
presence of increasing concentrations of .-NMMA. This increase in consumption of NADPH is
also consistent with the reported failure of .-NMMA to inhibit the reduction of Cytochrome C by
purified pituitary cell NOS [6]. We suggest that -NMMA may serve as a substrate for NOS and
that reducing equivalents derived from NADPH reduce Fe(III) ofNOS to Fe(II) which in turn may
activate oxygen for incorporation into :.NMMA to yield -Arginine and formaldehyde. It may also
be possible to convert -NMMA to N"-monomethy--citrulline (-NMMC) and NO by NOS in
pituitary cells. Additional studies are required to examine the possibility that -NMMA is
converted to -Arginine and formaldehyde or to -NMMC and NO with this in vitro system.
The reaction system containing 907 laM -NMMA and 333 laM Ca(II)3(3,5-DIPS)6 caused
NOS to oxidize NADPH at a faster initial rate than the system containing 0.9 mM CaClz (Figures
7, 7a, 8, 8a). This demonstrates that Ca(II)3(3,5-DIPS)6 is a better or more bioavailable source of
Ca than CaCI_ for the activation of NOS. As shown in Table 2, the initial rate of NADPH
oxidation in the reaction mixture containing 113 laM -NMMA increased as the concentration of
Ca(II)3(3,5-DIPS)6 was increased from 113 laM to 267 laM (Figures 9, 9a, 10, and 10a). These
initial rates are faster than the initial rate observed for the reaction raixture containing 0.9 mM
CaCI_ and 113 IuM k-NMMA, which further supports the possibility that Ca(II)3(3,5-DIPS)6 serves
as a more bioavailable form of Ca for NOS activation. The initial rate ofNADPH oxidation for the
system containing 533 gM Ca(II)3(3,5-DIPS)6 (Figures 12 and 12a) underwent a dramatic decrease
in comparison with the initial rate observed for the addition of 267 gM Ca(II)3(3,5-DIPS)6
(Figures 11 and a). The addition of this very large concentration of Ca(II)3(3,5-DIPS)6 appears
to have allowed the oxidation ofNADPH to NADP, however NADP is then reversibly reduced to
NADPH which is then oxidized to NADP again in a cyclic process until the NADPH is consumed.
Further studies of this system are needed to determine the mechanism of this cyclic oxidation-
reduction process which may be an interesting biochemical redox characteristic of the NOS
enzyme system.
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Since Ca(II)(3,5-DIPS)6 inhibited the aggregation of platelets and overcame the
aggregation effect of -NMMA, it is concluded that Ca(II)(3,5-DIPS)6 activated Calmodulin,
which in turn activated NOS leading to the synthesis ofNO, and inhibition of platelet aggregation.
The blockade of the effect of .-NMMA by the addition of Ca(II)3(3,5-DIPS)6 supports this
conclusion.
Demonstrating that Ca(II)(3,5-DIPS)6 increases the rate of NADPH oxidation by NOS
offers support for the suggestion that -Arginine is converted to -Citrulline and NO, a mechanism
consistent with the observation that Ca(II)(3,5-DIPS)6 inhibits platelet aggregation.
Since the addition of Ca(II)(3,5-DIPS)6 caused an increase in initial rate of NADPH
oxidation in comparison with the initial rate observed for the complete reaction mixture containing
equimolar CaClz, it is concluded that Ca(II)(3,5-DIPS)6 is a more bioavailable form of Ca in
activating Calmodulin, which in turn activates NOS.
Results obtained in these studies demonstrate that -NMMA does not inhibit the activity of
NOS in this in vitro system, but actually serves as a substrate for NOS and increases the rate of
oxidation ofNADPH by NOS. Although -NMMA has been reported to be a NOS inhibitor in in
vivo systems, it may act as a substrate for NOS in in vitro systems. Since -NMMA serves as a
oxidizable substrate for NOS, the conversion of -Arginine to -Citrulline and NO by NOS may be
impeded in vivo if the rate of oxidation of .-NMMA to -NMMC and NO is slower than the rate of
conversion of -Arginine to -Citrulline and NO or -NMMA simply serves as a reducible substrate
for NOS and this consumption of reducing equivalents serves to decrease the conversion of -
Arginine to -Citrulline and NO. Further studies of-NMMA metabolism by NOS in vitro should
include measuring the rate of NADPH oxidation in the presence of -NMMA alone, without -
Arginine, and measuring the formation ofNO using the Greiss test for metabolites of NO, nitrite
and nitrate, and the measurement of-Citrulline.
Results of the present studies suggest that Ca(II)(3,5-DIPS)6 may be useful in facilitating
activation of NOS and enabling NO-dependent physiological processes such as neuronal
transmission, consciousness, dilation of blood vessels, leukocyte destruction of invading pathogens
and cancer cells, leukocyte responses in inflammation, pain perception, and.decreasing platelet
aggregation. Decreasing platelet aggregation with Ca(II)(3,5-DIPS)6 may be a particularly useful
approach to preventing or treating cerebral and myocardial infarction and atherosclerosis consistent
with the suggestion of Buechler et al.[7].
Finally, this new spectrophotometric method for the study of NOS enzyme activity may
also be useful in examining other essential or non-essential metalloelement complexes for their
potential effects off NOS inhibition, modulation, or down-regulation.
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